基本信息
views: 337
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Prof. Dr. Dr. Torsten Haferlach is CEO of MLL, a central reference laboratory providing diagnostic services for physicians in Germany that processes some 50,000 samples — mostly leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms — each year. Three years ago, the institution adopted next-generation sequencing technologies to help keep up with demand to screen for molecular mutations; today, MLL is one of the largest 454 sequencing labs in Europe with seven instruments in accredited routine operations, and it has added two Illumina MiSeq instruments to its facility since the end of 2011.
According to Dr. Alexander Kohlmann, Laboratory Director for Next-Generation Sequencing at MLL, “The field is evolving to a situation where we’re no longer sequencing single genes but rather panels of genes.” Part of his job is to ensure that the laboratory can keep up with burgeoning demand from its customers. “Doctors are asking for information about many genes in parallel. They want the results for all these markers at the same time and not step by step,” he says, expecting a turn-around time of five to six days from sample receipt to sending out a report.
With that in mind, MLL has been developing a panel of genes linked to myeloid malignancies for research use on the RainDance Technologies targeted sequencing platform, starting with the RDT 1000 and more recently adding the higher-throughput ThunderStorm® instrument released this year.
The panel, which will be commercially available to other RainDance customers, consists of more than 25 genes. Haferlach and his team are targeting genes in which mutations are known to be medically actionable today based on information from scientific publications. “We developed the myeloid panel for research use in those malignancies where a lot of genes are already being requested today or where we see an unmet need to test these genes at a high level of sensitivity and throughput, providing actionable prognostic information to clinicians suitable to guide therapy in the near future,” Haferlach says.
Research Interests
Papers共 862 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Medizinische Genetikno. 1 (2024): 3-11
Nature Communicationsno. 1 (2024): 1-1
Blood Advancesno. 15 (2024): 4125-4128
ANNALS OF HEMATOLOGYno. 1 (2024): 363-365
medrxiv(2024)
JCO clinical cancer informatics (2024): e2400008-e2400008
JCO clinical cancer informaticsno. 8 (2024): e2300205-e2300205
Leukemia (2024)
Load More
Author Statistics
#Papers: 865
#Citation: 23917
H-Index: 75
G-Index: 142
Sociability: 8
Diversity: 3
Activity: 210
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn